02/18/2026
Begin lowering your VISCERAL FAT with an herbal extract from the mature hops flower only from me.
🚨 Major New Research Alert: Obesity Significantly Increases Risk of Severe and Fatal Infections
A major study recently published in The Lancet has uncovered a strong and concerning link between obesity and heightened vulnerability to serious infectious diseases.
Drawing on health data from more than 540,000 adults in Finland and the UK, followed for an average of 14 years, the researchers demonstrated that excess body weight markedly worsens outcomes across a broad spectrum of infections.
The key findings are striking:
• Adults with obesity (BMI 30 or higher) face a 70 percent higher risk of hospitalization or death from infectious diseases compared with those at a healthy weight (BMI 18.5 to 24.9).
• The risk rises sharply with greater obesity severity. People with class III obesity (BMI 40 or higher) experience approximately three times the risk of severe infection-related outcomes.
• This pattern appears across many common infections, including influenza, pneumonia, COVID-19, urinary tract infections, and gastroenteritis, though the association does not extend to HIV or tuberculosis.
• On a global scale, obesity is estimated to contribute to roughly 1 in 10 infection-related deaths, or about 10.8 percent in recent figures. In some nations the proportion is even higher: 1 in 6 in the UK and 1 in 4 in the US.
• If obesity were eliminated, up to 11 percent of infection-related deaths worldwide could potentially be prevented.
Professor Mika Kivimäki of University College London, who led the study, stated that obesity is a risk factor for a wide range of infectious diseases, suggesting broad biological mechanisms may be involved.
He explained that it is plausible obesity weakens the immune system's ability to defend against infectious bacteria, viruses, parasites, or fungi, resulting in more serious diseases.
Co-author Dr. Solja Nyberg highlighted the growing public health implications, noting that people living with obesity are significantly more likely to become severely ill or die from a wide range of infectious diseases.
As obesity rates continue to rise globally, so will the number of deaths and hospitalisations linked to obesity.
With two in three adults in many Western countries now overweight or obese, this connection represents a major yet often overlooked driver of infectious disease burden, a pattern that became especially clear during the COVID-19 pandemic when higher obesity prevalence aligned with elevated mortality.
The positive takeaway is that these risks are modifiable through sustained weight loss.
The most reliable path remains lifestyle-focused: prioritizing nutrient-dense whole foods, regular physical activity (especially strength training to preserve muscle), adequate sleep, stress management, and building sustainable habits over time.
These approaches not only support immune function but also avoid introducing additional pharmaceutical risks.
While some studies have explored medications like GLP-1 receptor agonists and noted associations with reduced serious infection rates (around 11 percent relative reduction in meta-analyses of randomized trials, linked to weight loss and better glycemic control), these drugs come with a substantial array of potential downsides.
Common issues include persistent gastrointestinal effects such as nausea, vomiting, diarrhea, constipation, and abdominal pain, which can cause dehydration, nutrient deficiencies, or force discontinuation.
More serious reported risks encompass pancreatitis (with recent data highlighting cases including fatalities), gallbladder disorders like gallstones, gastroparesis (delayed gastric emptying), acute kidney injury, and other emerging concerns such as vision-related issues or long-term safety questions that remain under scrutiny.
Many users also experience muscle loss, facial sagging, or other unintended changes, and compounded versions raise extra concerns around quality and dosing accuracy.
Given these trade-offs, a cautious, non-pharmacological emphasis makes sense for many: focus on root-cause lifestyle changes that empower long-term health without added medication burdens.
The researchers call for urgent action, including policies that improve access to affordable nutritious food and opportunities for physical activity, stronger vaccination recommendations for individuals living with obesity, and greater integration of obesity management into strategies for preventing and controlling infectious diseases.
This is not a matter of blame; it is a call grounded in robust evidence.
Obesity is a changeable risk factor, and addressing it effectively through sustainable means could avert hundreds of thousands of preventable deaths from severe infections each year.
🔗 Full Study: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02474-2/fulltext
🔗 Article: https://www.dailymail.co.uk/health/article-15542459/Obese-70-cent-higher-risk-serous-infection.html
